Index of Contributors

Aguilera, G. 173-186
Akbasak, B-S. 173-186
Allolio, B. 556-569
Altemus, M. 697-707
Anglade, G. 339-351
Arai, K. 352-363
Arcus, D. 485-490
Assenmacher, I. 41-54

Baffi, J. S. 313-326
Bakos, P. 192-203
Barbanel, G. 41-54
Beller, D. I. 472-484
Bellinger, D. L. 523-534
Belova, N. 386-395
Black, P. H. 472-484
Blackwell, J. M. 449-458
Britton, K. T. 92-104
Brownstein, M. J. 273-292

Calogero, A. E. 31-40
Campbell, I. L. 301-312
Carter, C. S. 82-91
Chancellor-Freeland, C. 472-484
Chautard, T. 105-114, 419-437
Chiang, C-S. 301-312
Chowdrey, 449-458
Chrousos, G. P. xv, 1-18, 82-91, 352-363, 438-448, 459-471, 491-511, 556-569, 640-647, 665-676, 716-729
Cizza, G. 491-511
Coghlan, J. P. 240-251
Compaan, J. 252-256
Conforti, N. 73-81
Crofford, L. J. 459-471
Culman, J. 204-218

Daoud, R. I. 105-114
De Souza, E. B. 372-385
Devaud, L. L. 257-272
DeVries, A. C. 82-91
Diamanti, E. 660-664
Dvori, S. 313-326

Earley, B. 55-72
Ely, D. L. 594-608
Eskay, R. L. 105-114, 419-437

Feldman, S. 73-81
Felten, D. L. 523-534
Felten, S. Y. 523-534
Friedman, E. M. 396-418
Friedman, T. C. 459-471
Frye, M. 677-696
Fukuhara, K. 131-158

Gaillet, S. 41-54
Gimeno, M. 386-395
Givalois, L. 41-54
Gold, P. W. xv, 491-511, 716-729
Gold, P. E. 512-522
Golden, L. 609-616
Goldstein, D. S. 115-130, 131-158, 570-593
Gravanis, A. 166-172
Grino, M. 339-351
Groenink, L. 252-256

Hamelink, C. 105-114
Harbuz, M. S. 449-458
Hashimoto, K. 372-385
Heinrichs, S. C. 92-104
Hiremagalur, B. 131-158, 327-338

Ichinose, H. 159-165
Irwin, M. R. 396-418
Itoi, K. 204-218
Itzik, A. 73-81
Ixart, G. 41-54

Jacobson, L. 293-300
Jensen, E. W. 640-647
Jessop, S. 449-458
Jezova, D. 192-203
Jianlin, J. 609-616

Kagan, J. 485-490
Kage, R. 472-484
Kalivas, P. W. 617-625
Kamat, A. 386-395
Kapcala, L. P. 419-437
Karalis, K. 459-471, 551-555
Karanth, S. 386-395
Karl, M. 556-569
Kiss, A. 173-186
Kobayashi, K. 159-165
Koob, G. F. 92-104
Kopin, I. J. 19-30, 115-130, 131-158
Koplik, E. V. 240-251
Kotov, A. V. 240-251
Kvetňanský, R. 115-130, 131-158, 234-239, 327-338

Larsen, P. J. 449-458
Latronico, A. C. 352-363
Leeman, S. E. 472-484
Lehmann, R. 556-569
Leonard, B. E. 55-72

Licinio, J. 364-371, 716-729
Lightman, S. L. 449-458
Lolait, S. J. 273-292
Luo, X. 173-186
Lyson, K. 386-395

Mabry, T. R. 512-522
Madden, K. S. 523-534
Magiakou, M-A. 438-448
Magiakou, A. 556-569
Majzoub, J. A. 293-300, 551-555
Makino, S. 234-239
Malaval, F. 41-54
Margioris, A. N. 166-172
Martinez, C. 293-300
Mastorakos, G. 438-448
McCann, S. M. 386-395
McCarty, R. 512-522
Mekaouche, M. 41-54
Menzaghi, F. 92-104
Morrow, A. L. 257-272
Muglia, L. J. 293-300

Nagatsu, T. 159-165
Nankova, B. 131-158, 327-338

O'Carroll, A-M. 273-292
Oliver, C. 339-351
Olivier, B. 252-256

Pacák, K. 115-130, 131-158
Palkovits, M. 115-330, 313-326
Paul, S. M. 257-272
Paulmyer-Lacroix, O. 339-351
Peeke, P. M. 665-676
Pich, E. M. 92-104
Polyntsev, Yu. V. 240-251
Post, R. M. 234-239, 677-696
Prasad, B. M. 617-625
Purdy, R. H. 257-272
Putnam, F. W. 708-715

Reincke, M. 556-569
Rettori, V. 386-395
Riga, D. 535-550
Riga, S. 535-550
Rivier, C. 187-191
Roberts, R. L. 82-91
Rosen, J. 677-696
Rubinow, D. R. 648-659

Sabban, E. L. 131-158, 327-338
Salieva, R. M. 240-251
Sano, H. 459-471
Sapolsky, R. M. 626-639
Schmidt, P. J. 648-659
Siaud, P. 41-54
Skultetyova, I. 192-203
Smith, M. A. 234-239, 677-696
Snidman, N. 485-490
Song, C. 55-72
Sorg, B. A. 617-625
Sternberg, E. M. 365-371
Stournaras, C. 166-172
Stratakis, C. A. 1-18
Sudakov, K. V. 240-251
Szafarczyk, 41-54

Takao, T. 372-385
Taymans, S. E. 82-91
Tokarev, D. I. 192-203
Tolis, G. 660-664
Torda, T. 105-114
Tsigos, C. 352-363

Ulibarri, C. 617-625
Unger, T. 204-218

Van der Gugten, J. 252-256
van der Heyden, J. 252-256
Venihaki, M. 166-172
Vigas, M. 192-203
Viskupic, E. 131-158

Webster, E. A. 352-363, 459-471
Weidenfeld, J. 73-81
Weiss, S. R. B. 677-696
Wheatley, D. 609-616
Wilder, R. L. 459-471
Williams, J. R. 82-91
Wong, M. 716-729

Yadid, G. 115-130

Zethof, T. 252-256
Zhu, G. F. 472-484
Zukowska-Grojec, Z. 219-233

Subject Index

AADC, *see* Aromatic L-amino acid decarboxylase
Acetylcholine (ACh), 32-33
Acetylcholinesterase (AChE), 32
ACh (acetylcholine), 32-33
AChE (acetylcholinesterase), 32
ACTH (adrenocorticotrophin, corticotropin), 2, 339
  circulating, 3
  elevated in intensive care unit patients, 556-564
  plasma
    basal, in depression, 720
    stressors and, 118, 119, 121-127
  receptor (MC2R), 359
  receptor mutations causing ACTH resistance, 354-355
  receptor regulation, 357
  receptor signaling pathway, 353-354
  release, central regulation of, 41-52
  resistance, ACTH receptor mutations causing, 354-355
  responses following adrenalectomy, 73-79
  secretagogues of, 442
  stimulation test, 495
  stress and, 23
ACTH-CORT stress responses, 44-51
Acute stress, 449-450
Adjuvant-induced arthritis (AIA), 188-190, 452-456
Adolescence, 5
Adrenal activity
  corticotropin-releasing hormone actions independent of, 405
  in prairie voles, 83, 84
  reproductive activation and, 84-86
Adrenal hormones
  monogamy and, 87-88
  pair bonding and, 87
Adrenal steroidogenesis, shift in, 558
Adrenalectomy
  ACTH responses following, 73-79
  bilateral, 133
Adrenocortical neoplasms, tumorigenesis in, 356-357
Adrenocorticoid hormones, mammalian monogamy and, 82-89
Adrenocorticotrophin, *see* ACTH
Adrenomedullary chromaffin cells, opioid effects on, PC12 cell line model for, 166-170
Affect, regulation of, stress system and, 4-5
Affective disorders, 677-679
  stress sensitization in, 682-685
  temporal aspects of, 677-694
Age-dependent increase of lipofuscin pigments, 546
Age-related changes in plasma catecholamines, 514
Age-related deficits in learning and memory, 515-520
Aging, 491
  catecholaminergic alterations with, 498-499
  decreased stress responsivity and, 491-508
  hypothalamic-pituitary-adrenal axis alterations with, 505-507
  hypothalamic-pituitary-adrenal axis and, 492
  immune decline and, 406-407
  immune system in, sympathetic nervous system interaction with, 523-532
  memory and, 512-520
  sympathoadrenal activity and, 641-642
AIA (adjuvant-induced arthritis), 188-190, 452-456
AII (angiotensin II) receptors, 173-183
Alcohol, hippocampal neurotoxicity and, 105-112
Aldosterone, 182
  secretion, 182, 183
Allopregnanolone (3α-hydroxy-5α-pregnan-20-one) (3α,5α-THP), 257-267
Alzheimer's disease, 546
Amenorrhea, distress, 660-662
Aminoglutethimide, 133
Amygdalofugal pathways, 96
Anabolism/catabolism ratio, 535
Angiotensin II (AII) receptors, 173-183
Animal model of overproduction of corticotropin-releasing factor, 99,100
Antagonic-Stress synergistic formula, 537, 546-547
Anti-orthostatic tail-restraint (AOR), 44, 46
Antiaging neurometabolic therapy, 535-547
Antidepressant drugs, mechanism of action of, 716-726
Antistress neurometabolic therapy, 535-547
Anxiety, 1
Anxiety disorders
  effect of lactation on, 702
  neuropeptides in, 697-703
AOR (anti-orthostatic tail-restraint), 44, 46
Arginine-vasopressin (AVP), 2, 273, 419
  mRNA expression, 341
  receptors
    characterization of, 274-281

molecular biology of, 273-288
structural characteristics of, 281-285
tissue distribution of mRNAs encoding, 285-288
systemic secretion of, recombinant IL-6 and, 439-442
Aromatic L-amino acid decarboxylase (AADC), 133-134, 159
Arthritis
adjuvant-induced, 188-190, 452-456
inflammatory, *see* Inflammatory arthritis
rheumatoid, *see* Rheumatoid arthritis
Astrocytes, 302
Autonomic nervous system, corticotropin-releasing hormone activation of, 405-406
AVP, *see* Arginine-vasopressin

BALs (blood alcohol levels), 106-107
BBB (blood-brain-barrier) integrity, 304-307
BDNF (brain-derived neurotrophic factor), 234-238
BE, *see* Beta-endorphin
Behavior patterns, physiological correlates of, 599-600
Behavioral changes, 2
Benzodiazepines (BZDs), 37-38
stress-induced hyperthermia and, 253-255
Beta-endorphin (BE), 240
after DSIP injection, 242-243
Bicuculline, 37
Bilateral adrenalectomy, 133
Blood alcohol levels (BALs), 106-107
Blood-brain-barrier (BBB) integrity, 304-307
Brain, corticotropin-releasing hormone action in, 404-405
Brain-derived neurotrophic factor (BDNF), 234-238
Brain-endocrine-immune axis, IL-1 receptors in, 372-382
Brain melanocortin receptors, 357-360
Brain sites for behavioral effects of corticotropin-releasing factor, 95-98
Brain stem catecholaminergic cells, nociceptive inputs to, 320, 322, 323
Breaking strain, 19
BZDs, *see* Benzodiazepines

C-fos expression, pain-induced, 313-323
c-fos immunoreactivity, 315-320, 321
CAC (chronic alcohol consumption), *see* Alcohol
cAMP modulation, 373
Capsaicin, 460, 480
stress-induced macrophage function and, 479-481
Carbachol, 387
Carbamazepine, anticonvulsant effects of, 668, 690
Cardiovascular responses to stress, 594-604
Cardiovascular risk factors and disease, 600-602
Carrageenin, 461
CAs, *see* Catecholamines
Catecholamine biosynthetic enzymes
mRNA levels for, 330-335
stress-elicited induction of, 327-337
Catecholamine system enzymes
alterations in, 159-162
Catecholaminergic alterations with aging, 498-499
Catecholaminergic cells, brain stem, nociceptive inputs to, 320, 322, 323
Catecholaminergic fibers, 313-314
Catecholamines (CAs), 33-34
glucocorticoid administration and, 139-145
O-methylated metabolites of, 578
plasma, 493
age-related changes in, 514
synthesis, hypothalamic-pituitary-adrenal axis and, 145-149
urinary, 106
CD5+ T cells, 531
CE (cerebrovascular endothelial) cells, 307
Cellular immune function, 399-404
Central nervous system (CNS), 2, 3
corticotropin-releasing factor as neurotransmitter in, 92-93
cytochrome P4502E1 endangerment, 111-112
diseases, 301
cytokines in, 301-310
ethanol-induced toxicity models, 109-112
Central stress reactions, tachykinins and, 214-216
Cerebrospinal fluid (CSF)
neuropeptides in obsessive-compulsive disorder, 698-701
norepinephrine in, 573-574
Cerebrovascular endothelial (CE) cells, 307
ChAT (choline acetyltransferase), 32
China, Wheatley Stress Profile in, 611-616
Choline acetyltransferase (ChAT), 32
Chronic alcohol consumption (CAC), *see* Alcohol
Chronic fatigue syndrome, 722-723
Chronic inflammatory stress, 450-456
Chronic stress, hemodynamics of, 672-673
CIBS (cocaine-induced behavioral sensitization), 679-680

Clinical assessment
advantages and disadvantages of techniques, 583-584
of sympathetic responses to stress, 570-585
CNS, *see* Central nervous system
Cocaine-induced behavioral sensitization (CIBS), 679-680
Cocaine sensitization, 679-680
Compensatory adaptation, seizure episode and, 687-688
Con A-stimulated IL-2 production, 530
Contingent tolerance, 687
Coping
low, 600-602
and stress connection, 597-598
Corticosterone (CORT), 43-51
after DSIP injection, 243, 244
assay of concentrations, 59
levels in serum, 61, 65
Corticotropin, *see* ACTH
Corticotropin-releasing factor (CRF), 55-69, 196, 339, 449
animal model of overproduction of, 99, 100
antagonists, behavioral effects of, 94-95
in behavioral aspects of stress, 92-101
behavioral effects of, 93-94
brain sites for, 95-98
endogenous, stressor specificity and, 98, 99
hypothalamic, in immune-mediated diseases, 449-456
mRNA expression, 340, 342
mRNA levels, 501
as neurotransmitter, 92-93
steady-state mRNA hypothalamic, 498
stimulation test, 494-495
synthesis, 347
Corticotropin-releasing hormone (CRH), 2, 31, 106, 293, 419
action in brain, 404-405
actions independent of adrenal activation, 405
activation of autonomic nervous system, 405-406
administration of, 5
autonomic responses to, 398
behavioral responses to, 398
cytokines and, 387-389
deficiency, creation of mouse model of, 296-298
discovery of, 717-718
expression in joints, 461-464
expression in synovial fluids, 464-468
gene
molecular and transgenic studies of, 293-298
transcriptional regulation of, 294-296
histamine and, 35
immune system and, 460-461
local expression of, in inflammatory arthritis, 459-468
in melancholic and atypical depression, 716-726
modulation of immune function, 398-404
modulation of immunity, 409-411
neurotransmitter regulation of, 31-38
ovine, 718-726
placental, regulation by steroids, 551-554
role in depression, 720-721
role in stress-induced immunosuppression, 396-411
stress and, 397-398
Cortisol, 135, 552
elevated in intensive care unit patients, 556-564
plasma, plasma IL-6 and, 565
CP 96, 345, 215-216
CRE (cyclic AMP responsive element), 294-296
CRF, *see* Corticotropin-releasing factor
CRH, *see* Corticotropin-releasing hormone
CRH41 release, 42-44
Critical stress level, 19
Cross-sensitization
dopamine transmission and, 617-620
hypothalamic-pituitary-adrenal axis and, 618, 620-622
CSF, *see* Cerebrospinal fluid
Culture, stress and, 609-616
Cushing's disease, 719
hypercortisolism in, 721-722
Cushing's syndrome, 668
Cyclic AMP responsive element (CRE), consensus, 294-296
CYP2E1, 111-112
Cytochrome P4502E1 CNS endangerment, 111-112
Cytokine-induced neurodegenerative disease, paradigm for, 302-307
Cytokine pathways, 364-365
Cytokines, 301, 364, 420-424
in central nervous system diseases, 301-310
corticotropin-releasing hormone and, 387-389
GH release and, 391
IFN family of, 307
immune system and, 420-424
inflammatory, 438
LHRH release and, 389-391
macrophages and, 473-477
mechanism of action of, pituitary hormone secretion in infection and, 386-393

neuropathogenic potential of, 307-309
pituitary gland and, 387, 392
Cytoplasm, 535

DA, *see* Dopamine
DBH, *see* Dopamine-β-hydroxylase
Defective reaction, 1
Defense reaction, 204
Delta-sleep-inducing peptide (DSIP), 240-251
Deoxycortisone, 258
Depression
basal plasma ACTH in, 720
corticotropin-releasing hormone in, 720-721
hypercortisolism in, 717
major, 719
melancholic, 4, 716-726
seasonal, 5
Depression-related immune decline, 407-409
DHPG, *see* Dihydrophenylglycol
Diazepam, 253-255
Dihydrophenylglycol (DHPG), 133-134, 135-136
norepinephrine turnover and, 577-578
α,21-Dihydroxy-5α-pregnan-20-one (THDOC), 257-266
3,4,-Dihydroxy-L-phenylalanine (DOPA), 328, 578-579
Dihydroxyphenylacetic acid (DOPAC), 133-134, 135-136, 579-580
Direct sympathetic nerve recording, 580-581
Dissociation, 708
psychobiology of, 710-711
relationship of traumatic stress to, 709-710
Dissociative states of consciousness, psychobiology of, 711-712
Distress amenorrhea, 660-662
Distress-related gonadal dysfunction, 660-662
Dithiothreitol (DTT), 174
DOPA (3,4-dihydroxy-L-phenylalanine), 328, 578-579
DOPAC (dihydroxyphenylacetic acid), 133-134, 135-136, 579-580
Dopamine (DA), 575-576
transmission, cross-sensitization and, 617-620
urinary, 576-577
Dopamine-β-hydroxylase (DBH), 133-134, 159, 328
gene in mice, 161
DOPEG, *see* Dihydrophenylglycol
DSIP (delta-sleep-inducing peptide), 240-251
DTT (dithiothreitol), 174
Duodenal ulcer, 642-643
Dwarfism, psychosocial (PD), 8
Dynorphins, 167-168
Dysphoria, 4

E, *see* Epinephrine
EAE (experimental allergic encephalomyelitis), 451
Eledoisin, 205
Emotional stress, 244-248
EMS (eosinophilia-myalgia syndrome), 451
Endocrine reactions, substance P and, 213-214
Endogenous IL-6 secretion, hypothalamic-pituitary-adrenal axis and, 443-444
Eosinophilia-myalgia syndrome (EMS), 451
EPI, *see* Epinephrine
Epinephrine (E), 33
memory storage process modulation by, 512-513
plasma, 574-575
role in age-related deficits in learning and memory, 515-520
Episode cyclicity, tolerance phenomena and, 689-692
Episode reemergence during prophylactic treatment, 685-687
Ethanol abuse and dependence, neurosteroids in, 266-267
Ethanol-induced CNS toxicity models, 109-112
Ethanol infusion studies, intragastric, 107-109
Ether-laparotomy stress, 375-377
"Euthyroid sick" syndrome, 6-7
Excessive reaction, 1
Experimental allergic encephalomyelitis (EAE), 451

F-SP (fluorescein-labeled SP), 477
Fatigue, 21
Fatigue states, 722-723
Feedback inhibition, glucocorticoid induced, 144
FFA (free fatty acids), 672
Fixed stress method, 19
Flesinoxan, 253-255
Fluorescein-labeled SP (F-SP), 477
Forskolin, 373-375
Free fatty acids (FFA), 672

G-protein-coupled receptors, 281
GABA, 37-38
GAS (general adaptation syndrome), 21
Gastrointestinal function, stress system and, 10-13
GCs, *see* Glucocorticoids

General adaptation syndrome (GAS), 21
Glial fibrillary acidic protein (GFAP) vector, 302-307
Gliosis, 304
Glucocorticoid hippocampal endangerment model, 109-111
Glucocorticoid-induced feedback inhibition, 144
Glucocorticoids (GCs), 3, 105-112, 668
  administration, catecholamines and, 139-145
  secretion, social rank and, 630-636
Glucopenia, 116
GnRH (gonadotropin hormone releasing hormone), 5
Gonadal axis, stress system and, 6-7
Gonadal dysfunction, distress-related, 660-662
Gonadal steroids, 187-190
Gonadotropin hormone releasing hormone (GnRH), 5
Gonadotropin-releasing hormone, *see* LHRH
Gonadotropins, 187-190
Great Britain, Wheatley Stress Profile in, 611-616
Growth, stress effect upon, 671
Growth axis, stress system and, 7-8
Growth hormone release, cytokines and, 391

HA, *see* Histamine
Heart rate variability, spectral analysis of, 581
Heat shock protein (HSP) response, 597, 598
Hippocampal endangerment model, glucocorticoids, 109-111
Hippocampal neurotoxicity, 105-112
  alcohol and, 105-112
Histamine (HA), 34-35, 50
  corticotropin-releasing hormone and, 35
Homeostasis, 1, 19
HPA, *see* Hypothalamic-pituitary-adrenal axis
HPG, *see* Hypothalamic-pituitary-gonadal axis
HPO (hypothalamic-pituitary-ovarian) axis, 649-650
HPT, *see* Hypothalamic-pituitary-thyroid axis
HSP (heat shock protein) response, 597, 598
5-HT (serotonin), 36-37
Humoral immune function, 401-404
3α-Hydroxy-5α-pregnan-20-one (3α,5α-THP) (allopregnanolone), 257-267
6-Hydroxydopamine (6-OHDA), 406
Hypercatabolism, 535
Hypercortisolism, 8, 557
  in Cushing's disease, 721-722
  in depression, 717
  obesity and, 665-673
  social subordinance and, 626-636
Hypertension, psychosocial stress and, 594-597
Hyperthermia, stress-induced, in mice, 252-255
Hypoanabolism, 535
Hypoandrogenism, 671
Hypothalamic-pituitary-adrenal (HPA) axis, 2, 4-5, 41-42, 73, 107, 352, 368, 650-651, 716-717
  activation, 9-10, 339
  aging and, 492
  alterations with aging, 505-507
  catecholamine synthesis and, 145-149
  cross-sensitization and, 618, 620-622
  dysfunctional, 13-14
  endogenous IL-6 secretion and, 443-444
  function, neurosteroid regulation of, 263-264
  immune/inflammatory reaction on, 438-446
  impairment, in aging, 491-508
  interaction with sympathoadrenal system, 131-150
  melanocortin receptors in, 352-361
  in obsessive-compulsive disorder, 697-698
  protective role of, against lethality, 419-432
  recombinant IL-6 and, 439
  regulation of
    molecular aspects of, 339-348
    in rat fetuses, 343-344
    in rat postnatal period, 344-348
  severe illness and, 556-564
  stressor effect on norepinephrine release in, 115-127
Hypothalamic-pituitary-gonadal (HPG) axis, 187-190, 368
  in severe illness, 565-566
Hypothalamic-pituitary-ovarian (HPO) axis, 649-650
Hypothalamic-pituitary-thyroid (HPT) axis, 651-652
  in severe illness, 564-565
Hypothalamic tachykinins, 204-216
Hypothalamus, 204, 428

Ia antigen expression, 473
ICE (IL-1β converting enzyme), 366
ICU, *see* Intensive care unit patients
IFN family of cytokines, 307
IGF-1 (insulin-like growth factor 1), 671
IgG anti-KLH antibody response, 527
IgM anti-KLH antibody response, 526
IL-1 (interleukin-1), 364-367, 372, 420-424

production, 372
receptors
in brain-endocrine-immune axis, 372-382
modulation of
by infection, 377-380
by stress, 373-377
IL-1β (interleukin-1β) converting enzyme (ICE), 366
IL-2 (interleukin-2) production, Con A stimulated, 530
IL-3 (interleukin-3), 309
IL-6 (interleukin-6), 302, 364
endogenous secretion, hypothalamic-pituitary-adrenal axis and, 443-444
plasma, plasma cortisol and, 565
production, 387
recombinant, *see* Recombinant IL-6
transgenic expression of, 302-307
Imipramine, 724
Immobilization stress, 328-329
Immune decline
aging and, 406-407
depression-related, 407-409
Immune function
cellular, 399-404
corticotropin-releasing hormone modulation of, 398-404
humoral, 401-404
stress system and, 12, 13-14
Immune-mediated diseases, hypothalamic corticotropin-releasing factor in, 449-456
Immune reaction on hypothalamic-pituitary-adrenal axis, 438-446
Immune response, substance P and, 476-477
Immune stimuli, immune system activation against, 424-431
Immune system
activation against immune, infectious, and inflammatory stimuli, 424-431
in aging, sympathetic nervous system interaction with, 523-532
changes in, 56
corticotropin-releasing hormone and, 460-461
cytokines and, 420-424
Immunity, corticotropin-releasing hormone modulation of, 409-411
Immunoreactivity, *c-fos*, 315-320, 321
Immunosuppression, stress-induced, *see* Stress-induced immunosuppression
Infantile malnutrition, 8
Infection, 386
modulation of IL-1 receptors by, 377-380
pituitary hormone secretion in, mechanism of action of cytokines and, 386-393
Infectious stimuli, immune system activation against, 424-431
Inflammation, 438, 459
Inflammatory arthritis, local expression of corticotropin-releasing hormone in, 459-468
Inflammatory cytokines, 438
Inflammatory disease, susceptibility to, 364-369
Inflammatory reaction on hypothalamic-pituitary-adrenal axis, 438-446
Inflammatory stimuli, immune system activation against, 424-431
Inflammatory stress, chronic, 450-456
Inflammatory synovitis, 464
Inhibitory avoidance training, 515-518
Insulin-like growth factor 1 (IGF-1), 671
Intensive care unit (ICU) patients, 556
ACTH elevated in, 556-564
cortisol elevated in, 556-564
scoring systems (TISS), 563, 566
steroid secretion pattern in, 559
Interleukins, *see* IL *entries*
Intragastric ethanol infusion studies, 107-109

Joints, corticotropin-releasing hormone expression in, 461-464

Kappa opioid binding sites, 169
Ketanserin, 36
Keyhole limpet hemocyanin (KLH), 401-402

LAA (leukocyte adhesiveness/aggregation), 56, 59, 61, 64, 67-69
Lactation
effect of, on anxiety disorders, 702
inhibition of stress response during, 701-702
Large dense-core granules, 219
Law enforcement study, 602-603
Learning, age-related deficits in, 515-520
Leishmaniasis, 451
Lethality, protective role of hypothalamic-pituitary-adrenal axis against, 419-432
Leukocyte adhesiveness/aggregation (LAA), 56, 59, 61, 64, 67-69
LHRH (gonadotropin-releasing hormone, luteinizing hormone releasing hormone), 187-190
cytokines and, 389-391
Limbic structures in ACTH responses following adrenalectomy, 73-79
Lipofuscin, 535
Lipofuscin pigments, age-dependent increase of, 546

Lipopolysaccharide (LPS), 377-380
Luteal phase ovarian steroid levels, 652-653
Luteal-phase-specific abnormalities in menstrual cycle related mood disorders, 649-642
Luteinizing hormone releasing hormone, *see* LHRH
LVP (lysine vasopressin) receptor, 280
Lymphocyte proliferation, 58-59
Lysine vasopressin (LVP) receptor, 280

Macrophage function, stress-induced, capsaicin and, 479-481
Macrophages, 472-473
  cytokines and, 473-477
  stress-induced alterations in, 472-477
  substance P and, 474-479
Male-male dominance interactions, 634
Malnutrition, infantile, 8
Mammalian monogamy, 82-89
MBIG (meta-iodo-benzylguanidine), 581
MC2R (ACTH receptor), 359
MC3R (melanocortin 3 receptor), 357, 358
MC4R (melanocortin 4 receptor), 358, 359
MC5R (melanocortin 5 receptor), 358, 359-360
Meclofenoxate, 546
Melancholic depression, 4, 716-726
Melanocortin 3 receptor (MC3R), 357, 358
Melanocortin 4 receptor (MC4R), 358, 359
Melanocortin 5 receptor (MC5R), 358, 359-360
Melanocortin receptors
  brain, 357-360
  cloning of, 352-353
  in hypothalamic-pituitary-adrenal axis, 352-361
Memory
  age-related deficits in, 515-520
  aging and, 512-520
Memory storage process modulation by epinephrine, 512-513
Menstrual cycle related mood disorders (MRMD)
  luteal-phase-specific abnormalities in, 649-652
  neuroendocrinology of, 648-647
Meta-iodo-benzylguanidine (MBIG), 581
Metabolic syndrome, visceral obesity and, 666-667
Metabolic syndrome X (MS-X), 8
Metabolism, stress system and, 8-10
Metergoline, 36
Methoxyhydroxyphenylglycol (MHPG), 133-134, 135-136
N-Methyl-D-aspartate (NMDA) receptors, 110-111
  pregnenolone sulfate and, 264-265
MHPG (methoxyhydroxyphenylglycol), 133-134, 135-136
Microneurography, 580
  sympathetic, 583-584
Mifepristone (RU 486), 551, 553
Mitogen-induced proliferation, 529
Monogamy
  adrenal hormones and, 87-88
  mammalian, 82-89
Monokines, 472
Morris swim task training, 518-520
MRMD, *see* Menstrual cycle related mood disorders
MS-X (metabolic syndrome X), 8

NE, *see* Norepinephrine
Neuroactive steroid modulators of stress response, 257-258
Neuroactive steroids, 257-258
Neurochemical methods, sympathetic responses to stress and, 570-580
Neurodegenerative disease, cytokine induced, paradigm for, 302-307
Neuroendocrine function, visceral obesity and, 667-670
Neuroendocrinology of menstrual cycle related mood disorders, 648-657
Neurohumoral responses to stress, 594-604
Neuroimmune stress interactions, 364-369
Neurokinin A (NKA), 205-210
Neurokinin B (NKB), 205-206
Neurometabolic therapy, antistress and antiaging, 535-547
Neuronal organization of stress response, 313-323
Neuropathogenic potential of cytokines, 307-309
Neuropeptide τ (NPτ), 205
Neuropeptide K (NPK), 205
Neuropeptide Y (NPY), 219-231, 580
  clearance, 224
  stress and, 220-229
  vascular hypertrophy and, 229-230
Neuropeptides in anxiety disorders, 697-703
Neurosteroid regulation of hypothalamic-pituitary-adrenal axis function, 263-264
Neurosteroids, 257-267
  in ethanol abuse and dependence, 266-267
  stress response and, 259-261
Neurotransmitter, corticotropin-releasing factor as, 92-93
Neurotransmitter regulation of corticotropin-releasing hormone, 31-38
Neurotrophic factors, 234-238
Neutrophil phagocytosis, 58

Neutrotrophin-3 (NT-3), 234-238
Neutrotrophin-4 (NT-4), 234
Nissl bodies, 544
Nitric oxide synthase (NOS), 388
NKA (neurokinin A), 205-210
NKB (neurokinin B), 205-206
NMDA, *see N*-Methyl-D-aspartate receptors
Nociceptive inputs to brain stem catecholaminergic cells, 320, 322, 323
Nonosmotic stress, 193-194
Norepinephrine (NE), 33
  arterial clearance, 572
  in cerebrospinal fluid, 573-574
  plasma kinetics, 572-573
  release, stressor effects on, 115-127
  sympathetic responses to stress and, 570-572
  turnover, dihydrophenylglycol and, 577-578
  urinary, 574
NOS (nitric oxide synthase), 388
NPK (neuropeptide K), 205
NPT τ (neuropeptide τ), 205
NPY, *see* Neuropeptide Y
NSD-1015, 142
NT-3 (neutrotrophin-3), 234-238
NT-4 (neutrotrophin-4), 234
Nuclear medical imaging techniques, 581-583

O-methylated metabolites of catecholamines, 578
Obesity
  defined, 666
  hypercortisolism and, 665-673
  visceral, *see* Visceral obesity
Obsessive-compulsive disorder (OCD), 697-698
  CSF neuropeptides in, 698-701
  hypothalamic-pituitary-adrenal axis in, 697-698
OCD, *see* Obsessive-compulsive disorder
6-OHDA (6-hydroxydopamine), 406
"Open field" apparatus, 57
Opioid binding sites, kappa, 169
Opioid effects on adrenomedullary chromaffin cells, PC12 cell line model for, 166-170
OR (orthostatic restraint), 44, 46
Orotic acid, 546
Orthostatic restraint (OR), 44, 46
Osmotic stress, 193
Osteoporosis, 8-9
OT, *see* Oxytocin
Ovarian sterid levels, luteal phase, 652-653
Ovarian steroids, 653-656
Ovarian suppression, 653
Ovine corticotropin-releasing hormone, 718-726
Oxytocin (OT), 192
  receptors, characterization of, 274-281
  secretion, in response to stress, 192, 197-199
Oxytocin-like peptides, 274

Pain-induced *c-fos* expression, 313-323
Pair bonding, adrenal hormones and, 87
Paraventricular nucleus (PVN), 95-96
  regulation of function by AII, 178-181
  stressor effect on norepinephrine release in, 115-127
Pathological dissociation, 708-709
  traumatic stress and, 708-712
PC12 cell line, 166-167
  model for opioid effects on adrenomedullary chromaffin cells, 166-170
PD (psychosocial dwarfism), 8
Peripheral renin-angiotensin-aldosterone system, stress response and, 181-183
PET (positron-emission tomographic) scanning, 582-583
Phenylethanolamine *N*-methyltransferase (PNMT), 133-134, 159, 328
  gene in mice, 161-162
Physalaemin, 205
Physical changes, 2
Physiological correlates of behavior patterns, 599-600
Pituitary-adrenal function, baseline indices of, 494
Pituitary gland, cytokines and, 387, 392
Pituitary hormone secretion in infection, mechanism of action of cytokines and, 386-393
Placental corticotropin-releasing hormone regulation by steroids, 551-554
Plasma catecholamines, 493
Plasma epinephrine, 574-575
Pleasure, 4
PNMT, *see* Phenylethanolamine *N*-methyltransferase
Policy study, 602-603
Polyarthritis, 461-462
POMC, *see* Propiomelanocortin
Positron-emission tomographic (PET) scanning, 582-583
Posttraumatic stress disorder (PTSD), 234, 708-712
PPT (preprotachykinin) gene A, 205-206
Pregnane steroids, 258-267
Pregnenolone, 258
Pregnenolone sulfate, *N*-methyl-D-aspartate (NMDA) receptors and, 264-265
Preprotachykinin (PPT) gene A, 205-206

Prodynorphin transcript, 168
Progesterone, 551-552
Propiomelanocortin (POMC), 2, 339
  decreased gene transcription of, in young rat, 345-346
  mRNA levels, 502
  pituitary levels, 498
Psychobiology
  of dissociation, 710-711
  of dissociative and traumatic states of consciousness, 711-712
Psychosocial dwarfism (PD), 8
Psychosocial stress, 594-597
  defined, 644
  sympathoadrenal activity and, 640-646
Psychostimulants, stress sensitization and, 617-623
PTSD (posttraumatic stress disorder), 234, 708-712
PVN, *see* Paraventricular nucleus

RA, *see* Rheumatoid arthritis
Recombinant IL-6
  hypothalamic-pituitary-adrenal axis and, 439
  systemic secretion of arginine-vasopressin and, 439-442
Renin, 173-174
  stress response and, 181-182
Renin angiotensin system, 173-174
  stress response and, 174-181
Repeated stress, 450
Reproduction, stress effect upon, 671
Reproductive activation, adrenal activity and, 84-86
Reproductive axis, stress system and, 5-6
Rheumatoid arthritis (RA), 368
  CRH expression in synovial fluids and tissues with, 464-468
  hypothalamic-pituitary-adrenal axis and endogenous IL-6 secretion with, 443-444
Ritanserin, 36
RU 486 (mifepristone), 551, 553

SAM (sympathoadrenal medullary) system, 252-253
SAS, *see* Sympathoadrenal system
Seasonal affective disorder, 723-724
Seasonal depression, 5
Seizure episode, compensatory adaptation and, 687-688
Selye's hypothesis, 21-29
Sensitization
  cocaine, 679-680
  stress, *see* Stress sensitization
Serotonin (5-HT), 36-37
Severe illness, 556-566
  hypothalamic-pituitary-adrenal axis and, 556-564
  hypothalamic-pituitary-gonadal axis in, 565-566
  hypothalamic-pituitary-thyroid axis in, 564-565
Sex-hormone binding globulin (SHBG), 671
SIADH (syndrome of inappropriate antidiuretic hormone) secretion, 445
sIgM+ B cells, 531
SIH (stress-induced hyperthermia) in mice, 252-255
Skeletal muscle sympathoneural activity (SMSA), 580-581
SNS, *see* Sympathetic nervous system
Social development, temperament in, 485-489
Social primates, primacy of social stress and, 627, 628
Social rank
  glucocorticoid secretion and, 630-636
  stress-related physiology and, 628-630
Social stress, primacy of, social primates and, 627, 628
Social subordinance, hypercortisolism and, 626-636
Somatostatin, 375
SP, *see* Substance P
Spleen cell KLH-induced proliferation, 528
SR 48968, 215-216
Steroid levels, ovarian, luteal phase, 652-653
Steroid secretion pattern in intensive care unit patients, 559
Steroids
  ovarian, 653-656
  placental corticotropin-releasing hormone regulation by, 551-554
Strain and stress in physics, 20-21
Stress, 1
  ACTH (adrenocorticotrophin, corticotropin) and, 23
  acute, 449-450
  behavioral aspects of, corticotropin-releasing factor in, 92-101
  chronic, hemodynamics of, 672-673
  chronic inflammatory, 450-456
  and coping connection, 597-598
  corticotropin-releasing hormone and, 397-398
  culture and, 609-616
  definitions of, 19-22
  early effects of, 327
  effect upon reproduction, growth, and thyroid function, 671
  emotional, 244-248
  ether-laparotomy, 375-377

immobilization, 328-329
modulation of IL-1 receptors by, 373-377
neuropeptide Y and, 220-229
nonosmotic, 193-194
osmotic, 193
oxytocin secretion in response to, 192, 197-199
prolonged, 600-602
psychosocial, *see* Psychosocial stress
repeated, 450
responses to different magnitudes of, 26-29
scientific controversy about responses to, 22-29
Selye's hypothesis of, 21-29
and strain in physics, 20-21
sympathetic neuronal responses to, 29
sympathetic responses to, clinical assessment of, 570-585
sympathoadrenal system in, 131-150
term, 665
territorial, 595-596
traumatic, *see* Traumatic stress
vasopressin secretion in response to, 192-197, 199
Stress-elicited induction of catecholamine biosynthetic enzymes, 327-337
Stress-induced alterations in macrophages, 472-477
Stress-induced hyperthermia (SIH) in mice, 252-255
Stress-induced immunosuppression, 396-397
corticotropin-releasing hormone role in, 396-411
mechanisms of, 430-431
Stress-induced macrophage function, capsaicin and, 479-481
Stress interactions, neuroimmune, 364-369
Stress models, 643-645
Stress-related physiology, social rank and, 628-630
Stress response, 204, 257
division into components, 24
factors in, 1-2
inhibition of, during lactation, 701-702
mediators of, 204-216
neuroactive steroid modulators of, 257-267
neuroendocrinology of, 2-4
neuronal organization of, 313-323
neurosteroids and, 259-261
peripheral renin-angiotensin-aldosterone system and, 181-183
renin and, 181-182
renin angiotensin system and, 174-181
sustained, 44
Stress responsivity, decreased, aging and, 491-508
Stress sensitization, 681-685
in affective disorders, 682-685
psychostimulants and, 617-623
Stress system
activity, 1
dysregulation of, 4
gastrointestinal function and, 10-13
"generalized," 4
gonadal axis and, 6-7
growth axis and, 7-8
immune function and, 12, 13-14
metabolism and, 8-10
neuroendocrinology and pathophysiology of, 1-15
regulation of affect and, 4-5
reproductive axis and, 5-6
Stressor specificity, endogenous corticotropin-releasing factor and, 98, 99
Stressors, 41
plasma ACTH and, 118, 119, 121-127
Stroop procedure, variation of, 487
Substance P (SP), 204-216, 475
after DSIP injection, 241-242
endocrine reactions and, 213-214
function, 479
immune response and, 476-477
macrophages and, 474-479
Sustained stress response, 44
Swim task training, Morris, 518-520
Sympathetic innervation and function, visualization of, 581-583
Sympathetic microneurography, 583-584
Sympathetic nerve recording, direct, 580-581
Sympathetic nervous system (SNS), 3-4
interaction with immune system in aging, 523-532
in stress-induced immunosuppression, 396-411
Sympathetic neuronal responses to stress, 29
Sympathetic responses to stress
clinical assessment of, 570-585
neurochemical methods and, 570-580
norepinephrine and, 570-572
Sympathoadrenal activity
aging and, 641-642
in healthy subjects, 640-641
psychosocial stress and, 640-646
Sympathoadrenal medullary (SAM) system, 252-253
Sympathoadrenal system (SAS), hypothalamic-pituitary-adrenal axis interaction with, 131-150
Syndrome of inappropriate antidiuretic hormone (SIADH) secretion, 445

Synovial fluids, corticotropin-releasing hormone expression in, 464-468
Synovitis, inflammatory, 464

Tachykinin receptors, 206-209
Tachykinins, 205
  central actions of, 209-216
  central stress reactions and, 214-216
  hypothalamic, 204-216
  synthesis, tissue distribution, and physiological actions of, 205-206
Temperament in social development, 485-489
Temporal aspects of affective disorders, 677-694
Territorial stress, 595-596
TH, *see* Tyrosine hydroxylase
THDOC (3α,21-dihydroxy-5α-pregnan-20-one), 257-266
Theta rhythm, suppressed, 302-303
3α,5α-THP (3α-hydroxy-5α-pregnan-20-one) (allopregnanolon), 257-267
Threatened homeostasis, 1
Thyroid function, stress effect upon, 671
Thyroid-stimulating hormone (TSH), 671
TISS (intensive care unit patient scoring systems), 563, 566
Tolerance
  contingent, 687
  phenomena, episode cyclicity and, 689-692
Traumatic states of consciousness, psychobiology of, 711-712
Traumatic stress
  pathological dissociation and, 708-712
  relationship of, to dissociation, 709-710
Triple A syndrome, 356
Trophoblast cells, 552
TSH (thyroid-stimulating hormone), 671
Tumorigenesis in adrenocortical neoplasms, 356-357
Tyrosinase, 360
Tyrosine hydroxylase (TH), 133-134, 159, 328
  gene in mice, 160
  mRNA levels in locus ceruleus, 493
  multiple isoforms of, 159-160

Ulcer, duodenal, 642-643
United States, Wheatley Stress Profile in, 611-616
Urinary catecholamines, 106
Urinary dopamine, 576-577
Urinary norepinephrine, 574

V1 and V2 receptors, 275
Valproate
  anticonvulsant effects of, 689
  loss of efficacy to, 691
Variable stress method, 19
Vascular hypertrophy, neuropeptide Y and, 229-230
Vasopressin, 192
  arginine, *see* Arginine-vasopressin
  secretion, in response to stress, 192-197, 199
Vasopressin-like peptides, 274
Visceral obesity
  metabolic syndrome and, 666-667
  neuroendocrine function and, 667-670

Waist-to-hip (WHR) ratio, 667
Wheatley Stress Profile (WSP), 609-616
WHR (waist-to-hip) ratio, 667
WSP (Wheatley Stress Profile), 609-616